Morgans launches $10m Volpara Health raising
Volpara Health Technologies is in the market for a $10 million equity injection.
Retirement villages go 'vertical'
Developer taps the rising demand for retirement living.
Icon Group ramps up China push ahead of 2017 sale
Up-for-sale cancer care provider Icon Group turned the soil on the construction of a cancer centre in Guangzhou on Monday, Street Talk can reveal.
I learnt the meditation craze sweeping Wall St
Hedge fund billionaire Ray Dalio, Third Point's Dan Loeb and JPMorgan's Barry Sommers are all doing it.
NZ's EBOS taps UBS for HPS auction
New Zealand-based EBOS Group is said to have UBS in its corner as it prepares to make a play for pharmacy group HPS.
Marijuana is the other big winner in US vote
The victory for pot means US legislators will soon represent the interests of a marijuana industry.
BioCurate plots 'Team Oz' approach to innovation
BioCurate, an $80 million biopharmacy partnership between Monash and Melbourne universities, is already vetting new drug candidates.
Medibank revenue growth below expectations
Medibank CEO Craig Drummond has blamed a slowdown hitting the entire $20 billion industry for hindering revenue growth.
Mayne Pharma face US generics crackdown
Mayne Pharma shrugged off a US Government probe into it and other drug makers. We're not so confident.
KKR, Carlyle in race for Valeant's $1b-plus iNova: sources
KKR & Co is moving back into familiar territory with a bid for pharmaceutical group iNova.
